Breadcrumb

null Luis Souhami, MD

Honorary Investigator, RI-MUHC

Cancer Research Program

 

Keywords

central nervous system tumors • gynecological malignancies • genito-urinary malignancies

Research Focus

Luis Souhami received an Honorary Scientist appointment to the Research Institute of the McGill University Health Centre in 2025. This clinical researcher played a very important role in the development of stereotactic radiosurgery for brain metastases and in the introduction of 3D conformal radiotherapy and high dose rate brachytherapy in Canada. His contributions to original research in the field of radiation oncology are exemplary with more than 280 peer-reviewed publications and 40 book chapters and visiting professorships worldwide including Brazil, the United States, Canada, Saudi Arabia, Egypt and Ecuador. In 2011, his work has been recognized having earned the Gold Medal by the Brazilian Society of Radiotherapy, the Gordon Richards Lecture at the Canadian Association of Radiation Oncologists, and Fellow of the American Society for Radiation Oncology. He also received the International Recognition Award in radiotherapy from the Society of Neuro-Oncology of Latin America in 2016; the Gerald Bronfman Department of Oncology Research for Clinical Service Award in 2013; was inducted into the Academy of Medicine of Rio de Janeiro (Brazil) in 2018; and received the Cedars Award of Merit and Recognition for outstanding leadership in oncology in 2021. In May 2023, he was inducted into the National Academy of Medicine of Brazil. All these efforts whilst maintaining a strong and long-term service record as Associate Director of Division of Radiation Oncology (1991-2020). All these achievements serve as an example and inspiration for all current RI-MUHC members.

Luis Souhami’s research focuses on the treatment of tumors involving the brain, the gynecology area and the urogenital area.

Selected Publications

Click on Pubmed to see my current publications list

  • Turgeon G-A, Souhami L, Cury FL, Faria SL, Duclos M, Sturgeon J, Kassouf W. Hypofractionated IMRT in combined modality treatment for bladder preservation in elderly patients with invasive bladder cancer. Int J Radiat Oncol Biol Phys 88:326-331, 2014. PMID: 24411604.

  • Patel N, Souhami L, Mansure JJ, Duclos M, Aprikian A, Faria S, David M, Cury FL. Prostate-specific antigen bounce after high-dose-rate prostate brachytherapy and hypofractionated external beam radiotherapy. Brachytherapy 13:450-455, 2014. PMID: 25023396.

  • Owen S, Souhami L. The management of brain metastases in non-small cell lung cancer. Frontiers in Oncology 4:1-5, 2014. PMCID: PMC4164096.

  • Mason MD, Parulekar WR, Sydes MR, Brundage M, Kirkbride P, Gospodarowicz M, Cowan R, Kostashuk EC, Anderson J, Swanson G, Parmar MK, Hayter C, Jovic G, Hiltz A, Hetherington J, Sathya J, Barber JB, McKenzie M, El-Sharkawi S, Souhami L, Hardman PD, Chen BE, Warde P. Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer. J Clin Oncol. 2015 Feb 17. pii: JCO.2014.57.7510. [Epub ahead of print]. PMID: 25691677.

  • Viswanathan AN, Moughan J, Miller BE, Xiao Y, Jhingran A, Portelance L, Bosch WR, Matulonis UA, Horowitz NS, Mannel RS, Souhami L, Erickson BA, Winter KA, Small W Jr, Gaffney DK. NRG Oncology/RTOG 0921: A phase 2 study of postoperative intensity-modulated radiotherapy with concurrent cisplatin and bevacizumab followed by carboplatin and paclitaxel for patients with endometrial cancer. Cancer. 2015 Apr 6. doi: 10.1002/cncr.29337. [Epub ahead of print] PMID: 25847373.